BioFocus Announces Agreement with ChanTest
News Feb 07, 2013
BioFocus and ChanTest have announced an agreement which will enable BioFocus to offer ChanTest’s extensive cell line library (> 200 products) and Channel Panel™ profiling services.
This expands BioFocus’ offering in the fields of ion channel, GPCR and transporter targets for drug discovery.
“With access to ChanTest’s cell line collection and ion channel profiling, we have further augmented our suite of integrated drug discovery services, designed to deliver efficiency and success to our partners,” said Kate Hilyard, VP Biological Sciences, BioFocus.
Chris Mathes, Ph.D., M.B.A, Chief Commercial Officer, ChanTest, commented, “This collaboration with BioFocus fits well with ChanTest’s integrated CRO strategy, and we are delighted to partner with a company with such a strong reputation.”
Kidney Cancer Driver Could Lead to New Treatment StrategyNews
Scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change can lead to an overabundance of blood vessels, which help feed nutrients to the tumors. Their latest finding shows a potential new cancer-driving pathway.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019